Our Verification Process
Three Labs. Two Phases. One Standard.
Independently verified. Documented end-to-end.
AxonPeptide operates a two-phase verification system built around three separate analytical laboratories — designed to reduce overreliance on a single testing source and create stronger documentation transparency across our supply chain.
Why we use multiple independent labs.
Rather than relying on a single certificate of analysis from one laboratory, AxonPeptide's verification model uses multiple independent analytical partners — each serving a different role within the quality review process.
This is intentional. Single-source testing creates single-point-of-failure risk in a category where documentation transparency matters. By distributing analytical responsibility across three independent labs operating under different ownership, instrumentation, and methodology, we create structural accountability that no single certificate can provide on its own.
Primary molecule-specific validation.
Every batch first goes through documentation review and molecule-specific testing through ARS Labs before anything can move forward in the release process.
ARS Labs
Every batch receives a panel of analytical tests scoped to the compound:
- Glutathione products may undergo additional oxidation review.
- 5-Amino-1MQ (iodide salt) may receive moisture-content analysis.
- Larger-chain GLP compounds may undergo expanded sampling due to higher distribution velocity.
Supplier Vetting & Ongoing Quality Assurance
Beyond per-batch validation, ARS Labs plays a pivotal role in the supplier vetting process before any material enters the AxonPeptide supply chain — and in continuous supplier quality monitoring once a relationship is established. Per-batch analytical review tells us whether this batch meets our standards. Supplier review tells us whether the broader source is structurally capable of producing material that consistently meets them.
This upstream review function is part of why AxonPeptide's verification model is structural rather than terminal. The goal is not just to catch failures at release — it is to reduce the probability that failures occur in the first place by sourcing from suppliers whose process consistency has been analytically established and is being continuously monitored.
ARS Labs operates as an independent research-focused analytical laboratory led by qualified scientific researchers and is designed to prioritize deeper analytical review rather than functioning as a high-volume certificate-generation facility. ARS Labs is independently operated, with separation from AxonPeptide enforced by the Medical Stewardship Council.
A note on accreditation. ARS Labs is not currently positioned as a commercial laboratory accredited under ISO 9001 or ISO/IEC 17025. Its analytical framework is, however, designed around the principles emphasized in both standards — ISO 9001 for quality management system structure (document control, corrective action, internal review), and ISO/IEC 17025 for laboratory competence (instrument validation, traceability, method controls, and quality review of analytical work). Alignment with these principles is operational; formal accreditation is not claimed.
Independent cross-verification.
After batches clear Phase I, a randomized subset is selected for independent secondary verification through either Kovera Labs or Freedom Diagnostics — an additional integrity checkpoint on both our testing process and broader supply chain consistency.
One of AxonPeptide's secondary validation partners. After batches clear primary review, a randomized subset is routed to Kovera as part of Axon's ongoing quality control model.
- Validate consistency across released batches
- Strengthen quality oversight
- Reduce dependence on a single analytical source
- Create additional accountability within the supply chain
An additional independent verification layer within Axon's quality model. Select randomized batches may be routed through Freedom Diagnostics depending on product category, validation needs, and broader quality assurance initiatives.
- Additional analytical redundancy
- Broader verification oversight
- Stronger long-term batch monitoring
- Continuous supply chain consistency review
Scientific stewardship.
All analytical work is reviewed internally before release by an independent Medical Stewardship Council. Their role is to review testing documentation and ensure materials meet our release standards.
The Council's mandate is documentation review and release standards — not clinical, dosing, or therapeutic guidance. It also enforces the structural separation between AxonPeptide and ARS Labs.
If a batch fails our standards at any point, it does not get released. We absorb the loss and discard the material.
Why we built it this way.
Many companies in this category rely on a single COA from a single source. We intentionally built a broader model because we believe research materials deserve:
- Stronger documentation
- Independent verification layers
- Better traceability
- Greater transparency
- Continuous batch-level review
- Less reliance on single-point failure systems
No testing model can eliminate all uncertainty in this category. Our goal is not to claim certainty — it is to provide more transparency, stronger documentation, and multiple layers of independent review so researchers can make more informed decisions.
Verification you can review.
AxonVerified is our public-facing documentation portal where customers can review lot-specific certificates of analysis, batch documentation, verification records, and educational materials.